| Recruiting | 3 | 170 | Europe | XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght, XyloCore 0.7 or 1.5 or 2.0, 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution, Physioneal 40 or 35, Fixioneal 40 or 35, Dianeal, Balance, Bicavera, Bicanova, Equibalance | Iperboreal Pharma Srl | End Stage Renal Disease | 12/24 | 12/24 | | |
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) |
|
|
| Recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab | GlaxoSmithKline | Eosinophilic Granulomatosis With Polyangiitis | 10/25 | 11/25 | | |
